今年以来，面对海外主权基金的投资热情，我国从国家到地方层面密集出台有关政策，构建全方位、多层次的政策支持体 系，持续提升市场吸引力。与此同时，在政策红利与市场机遇的双重作用下，海外主权基金正持续加大对华投资力度，并呈 现"规模扩大、领域拓宽、深度加深"的显著特征。 接受《证券日报》记者采访的专家表示，海外主权基金持续加仓源于对中国经济韧性和创新能力的认可，而日趋完善的政 策体系则为投资提供了重要保障。未来，随着各项政策的落地实施，中国将进一步成为全球长期资本的重要目的地，投资领域 将更加广泛，合作深度将不断拓展，跨境资本合作也将为产业升级与经济高质量发展注入更强动力。 本报记者 田鹏 近日，在"深圳创投日"三周年活动上，深圳正式发布《深圳市推动海外主权基金来深投资工作方案（2025—2027）》，推 出"10条政策、24项措施"，并构建了招商引资、要素保障、监管服务三大协同机制，以深化存量合作、抢抓增量机遇，吸引海 外主权基金重点投向"20+8"产业集群、未来产业及基础设施领域。 这是年内我国积极吸引主权基金加码中国市场、深耕优质赛道的生动写照。 全球资本加码中国 投资结构呈现新特征 各地政策精准发力 构建引 ...

Market Overview - The A-share market showed mixed results on November 10, with the Shanghai Composite Index closing at 4018.6 points, up 0.53%, while the Shenzhen Component Index rose 0.18% to 13427.61 points. However, the ChiNext Index fell by 0.92% to 3178.83 points, and the North Star 50 Index decreased by 0.67% [1] - The total trading volume in the A-share market reached 21946.3 billion yuan, an increase of 1740.87 billion yuan compared to the previous trading day [1] Capital Flow - The main capital in the A-share market experienced a net outflow of 254.29 billion yuan, with an opening net outflow of 77.35 billion yuan and a closing net inflow of 11.65 billion yuan [2][3] - The CSI 300 index saw a net outflow of 87.96 billion yuan, while the ChiNext index had a net outflow of 147.56 billion yuan, and the Sci-Tech Innovation Board experienced a net outflow of 6.9 billion yuan [4][5] Sector Performance - Among the 13 sectors tracked, the food and beverage industry led with a net inflow of 109.94 billion yuan, reflecting a 3.49% increase [6][7] - Other sectors with significant net inflows included pharmaceuticals and biotechnology with 51.04 billion yuan, non-bank financials with 37.87 billion yuan, banks with 25.13 billion yuan, and agriculture, forestry, animal husbandry, and fishery with 24.72 billion yuan [7] - Conversely, the power equipment sector faced the largest net outflow of 211.06 billion yuan, followed by electronics with 154.94 billion yuan, and machinery with 76.27 billion yuan [7] Institutional Activity - Cambridge Technology recorded the highest net inflow of 7.58 billion yuan among individual stocks [8] - The top stocks with institutional net buying included Wanrun Technology and Tianji Shares, both showing a 10% increase [10][11] - Institutions showed interest in several stocks, with notable net buying in Prolo Pharmaceutical and Zhaoyan New Drug, indicating a positive outlook for these companies [13]

Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index closing at 4018.6 points, up 0.53%, while the Shenzhen Component Index rose 0.18% to 13427.61 points. The ChiNext Index fell by 0.92% to 3178.83 points, and the North Star 50 Index decreased by 0.67% [1] - Total trading volume in the A-share market reached 21946.3 billion yuan, an increase of 1740.87 billion yuan compared to the previous trading day [1] Capital Flow - The main capital in the A-share market experienced a net outflow of 254.29 billion yuan, with an opening net outflow of 77.35 billion yuan and a closing net inflow of 11.65 billion yuan [2][3] - The CSI 300 index saw a net outflow of 87.96 billion yuan, while the ChiNext and STAR Market experienced net outflows of 147.56 billion yuan and 6.9 billion yuan, respectively [4] Sector Performance - The food and beverage sector led with a net inflow of 109.94 billion yuan, showing a rise of 3.49%. Other sectors with significant inflows included biopharmaceuticals (51.04 billion yuan) and non-bank financials (37.87 billion yuan) [6][7] - Conversely, the power equipment sector faced the largest outflow of 211.06 billion yuan, followed by electronics with 154.94 billion yuan and machinery with 76.27 billion yuan [7] Stock Highlights - Cambridge Technology topped the list with a net inflow of 7.58 billion yuan [8] - Institutions actively participated in several stocks, with notable net purchases in Wanrun Technology (131.24 million yuan) and Tianji Technology (122.17 million yuan) [10][11] Analyst Ratings - Several companies received positive ratings from institutions, including Pro Pharmaceutical with a target price of 21.62 yuan, indicating a potential upside of 40.12% from its latest closing price [12]

Core Points - The Bioeconomy Index (970038) closed at 2270.57 points, up 1.89%, with a trading volume of 27.083 billion yuan and a turnover rate of 1.74% [1] - Among the index constituents, 47 stocks rose, with Jiuan Medical leading at a 10.01% increase, while 3 stocks fell, with Furui Shares leading the decline at 1.75% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 12.58%, latest price at 209.35 yuan, and a market cap of 253.825 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 4.87%, latest price at 105.06 yuan, and a market cap of 42.858 billion yuan [1] - Shentou Aoshang (sz002252) with a weight of 4.74%, latest price at 6.91 yuan, and a market cap of 45.868 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.55%, latest price at 31.84 yuan, and a market cap of 56.618 billion yuan [1] - Tigermed (sz300347) with a weight of 4.54%, latest price at 60.00 yuan, and a market cap of 51.662 billion yuan [1] - Shenzhen Technology (sz000021) with a weight of 4.16%, latest price at 27.84 yuan, and a market cap of 43.753 billion yuan [1] - Muyuan Foods (sz002714) with a weight of 3.62%, latest price at 51.67 yuan, and a market cap of 282.261 billion yuan [1] - Lepu Medical (sz300003) with a weight of 3.19%, latest price at 17.00 yuan, and a market cap of 31.338 billion yuan [1] - Aimeike (sz300896) with a weight of 3.16%, latest price at 156.50 yuan, and a market cap of 47.356 billion yuan [1] - Yuyue Medical (sz002223) with a weight of 3.07%, latest price at 35.97 yuan, and a market cap of 36.059 billion yuan [1] Capital Flow Summary - The Bioeconomy Index constituents experienced a net inflow of 1.505 billion yuan from main funds, while retail funds saw a net outflow of 1.087 billion yuan [3] - Notable capital flows include: - Shenzhen Technology (000021) with a net inflow of 145.514 million yuan from main funds [3] - Jiuan Medical (002432) with a net inflow of 309 million yuan from main funds [3] - Mindray Medical (300760) with a net inflow of 203 million yuan from main funds [3] - Muyuan Foods (002714) with a net inflow of 145 million yuan from main funds [3] - Tigermed (300347) with a net inflow of 80.614 million yuan from main funds [3]

Group 1 - The average stock price of the Sci-Tech Innovation Board is 40.80 yuan, with 69 stocks priced over 100 yuan, and the highest priced stock is Cambrian-U at 1391.50 yuan [2][3] - Among the stocks priced over 100 yuan, 37 stocks increased in price today, with an average increase of 0.56%, while 32 stocks decreased [2][3] - The average premium of the latest closing price relative to the issue price for stocks over 100 yuan is 502.60%, with the highest premiums seen in companies like Shunwei New Materials and Cambrian-U [2][3] Group 2 - The net outflow of main funds for stocks over 100 yuan today totaled 3.607 billion yuan, with the highest net inflows seen in companies like Purun Co. and Tengjing Technology [3] - The total margin balance for stocks over 100 yuan is 94.857 billion yuan, with Cambrian-U and SMIC having the highest margin balances [3][4] - The stock list of companies over 100 yuan includes various sectors, with a concentration in electronics, pharmaceuticals, and computers [2][3]

Summary of Key Points Core Viewpoint - In the past 10 days (from October 28 to November 10), overseas institutions have conducted research on 271 listed companies, with Huaming Equipment being the most focused, receiving attention from 80 overseas institutions [1]. Group 1: Research Activity - A total of 788 companies were researched by institutions in the last 10 days, with securities companies conducting research on 742 companies, accounting for the majority [1]. - Fund companies followed with research on 631 companies, while overseas institutions visited 271 listed companies [1]. - Huaming Equipment led the overseas research list with 80 institutions participating, followed by United Imaging Healthcare with 62 institutions [1]. Group 2: Stock Performance - The average stock price of companies researched by overseas institutions increased by 1.02% over the past 10 days [1]. - Notable stock price increases included Tianji Shares, which rose by 74.96%, and Aters, which increased by 71.51% [1]. - Conversely, 141 stocks experienced declines, with Juguang Technology showing the largest drop at 18.08% [1]. Group 3: Detailed Stock Data - The table lists various companies, their stock codes, the number of overseas institutions that researched them, latest closing prices, percentage changes, and their respective industries [1][2][3][4][5][6][7][8][9]. - For example, Tianji Shares (002759) had 2 overseas institutions researching it, with a closing price of 39.82 yuan and a rise of 74.96% [1]. - Huaming Equipment (002270) was researched by 80 overseas institutions, with a closing price of 27.40 yuan and a rise of 9.69% [2].

Investment Rating - The report maintains a "Buy" rating for the company [4][7] Core Views - The company's revenue for the first three quarters of 2025 reached 231.88 billion yuan, a year-on-year increase of 14.85%, with net profit attributable to the parent company at 57.51 billion yuan, up 24.50% year-on-year [11] - The growth is driven by the continuous release of innovative drug research results and accelerated overseas licensing cooperation, contributing to incremental performance [11] - The company has strengthened its innovative pipeline, with significant product approvals and a robust pipeline in various therapeutic areas [11] Financial Performance Summary - Revenue (in million yuan): - 2023A: 22,820 - 2024A: 27,985 - 2025E: 34,184 - 2026E: 38,303 - 2027E: 43,925 - Year-on-year growth rates: 2024A: 22.6%, 2025E: 22.2%, 2026E: 12.0%, 2027E: 14.7% [6][13] - Net profit (in million yuan): - 2023A: 4,302 - 2024A: 6,337 - 2025E: 8,755 - 2026E: 10,043 - 2027E: 11,403 - Year-on-year growth rates: 2024A: 47.3%, 2025E: 38.2%, 2026E: 14.7%, 2027E: 13.5% [6][13] - Earnings per share (in yuan): - 2023A: 0.65 - 2024A: 0.95 - 2025E: 1.32 - 2026E: 1.51 - 2027E: 1.72 [6][13] Strategic Developments - The company has achieved significant overseas licensing agreements, with over 800 million USD in upfront payments in the first three quarters of 2025 [11] - Recent collaborations include agreements with GSK, Glenmark, and Braveheart Bio, indicating a strong push towards internationalization [11] - The company is focusing on expanding its innovative drug portfolio, with multiple new drug applications accepted by NMPA [11]

Core Insights - Recent market style has shifted, with growth assets experiencing a "pain period" as sectors like electronics and biopharmaceuticals have seen significant declines since October [1] - The current adjustment in the dual innovation sector is attributed to structural differentiation within the market, where previous substantial gains have led to elevated valuation levels, setting the stage for a correction [1] - Short-term corrections are viewed as healthy adjustments following rapid increases, with the PE ratio of the Sci-Tech Innovation 50 Index dropping from 67 times on October 9 to 57 times on October 31, indicating a valuation repair that could build momentum for the next market phase [1] - Positive catalysts are emerging both domestically and internationally, including policy support emphasizing "technological self-reliance," potential expansion of domestic monetary policy easing, and the rapid rise of emerging industries such as artificial intelligence, semiconductors, and innovative pharmaceuticals [1] Investment Opportunities - The Sci-Tech Innovation 50 ETF (588080), the Growth Enterprise Board ETF (159915), and the Sci-Tech Innovation and Growth ETF (159781) are leading in scale among their tracked indices, offering good liquidity and a management fee rate of 0.15% per year, making them convenient options for investors looking to capitalize on "Sci-Tech + Growth" opportunities [2]

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report Through macro - fundamental analysis and technical analysis using tools such as the Golden Section line, horizontal line, and moving average, the report provides forecasts for the trends of various futures contracts on November 10, 2025, and also offers monthly trend expectations for some futures contracts in November 2025 [2]. 3. Summary by Relevant Catalogs 3.1 Futures Market Overview - On November 10, 2025, stock index futures are expected to oscillate and consolidate; rebar, coking coal, glass, crude oil, and soybean meal futures are expected to oscillate weakly; lithium carbonate futures are expected to oscillate strongly [1]. 3.2 Stock Index Futures - On November 7, 2025, major stock index futures contracts such as IF2512, IH2512, IC2512, and IM2512 showed weak oscillations, with slightly increased short - term downward pressure. On November 10, they are expected to oscillate and consolidate, and in November 2025, they are expected to oscillate widely [20][28]. 3.3 Treasury Bond Futures - On November 7, 2025, the ten - year and thirty - year treasury bond futures contracts showed downward trends. On November 10, they are expected to oscillate weakly [46][52]. 3.4 Precious Metal Futures - On November 7, 2025, gold and silver futures contracts showed upward trends. In November 2025, they are expected to oscillate widely, and on November 10, gold futures are expected to oscillate and consolidate, while silver futures are expected to oscillate and consolidate as well [55][60]. 3.5 Base Metal Futures - On November 7, 2025, base metal futures contracts such as copper, aluminum, zinc, nickel, and tin showed different trends. In November 2025, some are expected to oscillate widely and strongly, while others are expected to oscillate widely and weakly. On November 10, their trends vary, with some oscillating and consolidating, some oscillating weakly, and some oscillating strongly [64][77]. 3.6 Energy and Chemical Futures - On November 7, 2025, energy and chemical futures contracts such as crude oil, fuel oil, PTA, PVC, and methanol showed different trends. In November 2025, they are expected to oscillate widely, and on November 10, most are expected to oscillate weakly [125][136]. 3.7 Agricultural Product Futures - On November 7, 2025, agricultural product futures contracts such as soybean meal, rapeseed meal, and natural rubber showed weak oscillations. On November 10, they are expected to oscillate weakly or widely [138][144]. 3.8 Macro - economic Information - China's foreign trade, foreign exchange reserves, CPI, PPI, and other economic data have different trends, and there are also international events such as the US government shutdown and policy adjustments in various countries [9][10]. 3.9 Commodity Futures - related Information - The CSRC has approved the registration of platinum, palladium futures, and options at the Guangzhou Futures Exchange. Indian gold ETFs have seen record - breaking capital inflows, and international precious metal and crude oil futures have different price trends [17][18].

- The report mentions the construction of enhanced strategy ETFs, which are based on indices such as CSI 300, CSI 500, CSI 1000, SSE STAR 50, and others. These ETFs aim to outperform their respective benchmarks through quantitative strategies and factor-based enhancements [23][24][35] - The construction process involves selecting stocks from the underlying index and applying quantitative models to optimize the portfolio. The models may include factor analysis, risk control, and return enhancement techniques. Specific formulas or methodologies are not detailed in the report [23][24][35] - Evaluation of enhanced strategy ETFs indicates that 18 out of 51 ETFs outperformed their benchmarks last week. Over the past year, 30 out of 33 ETFs achieved positive excess returns, showcasing the effectiveness of the strategy [23][24][35] - Testing results for enhanced strategy ETFs show varying excess returns. For example, the CSI 300 Enhanced ETF achieved a weekly excess return of 0.64%, while the CSI 500 Enhanced ETF achieved 1.42%. Over the past year, the CSI 1000 Enhanced ETF delivered an excess return of 28.67%, and the Guozheng 2000 Enhanced ETF achieved 33.35% [24][35][36]